Ablevia biotech

Biotechnology Research • Vienna, Vienna, Austria • 1-10 Employees

Company overview

Headquarters	Maria-Jacobi-Gasse 1, Vienna, A- 1030, AT
Website	ablevia.com
SIC	873
Keywords	Drug Development, Licensing, Biotech, Precision Medicine, Rare Diseases, Personalized Medicine, Gene Therapy, Epitope Mapping, Preclinical Development, Anti-Drug Antibodies, Harmful Antibody Removal, Peptide Biotherapeutics
Employees	1-10
Socials

Key Contact at Ablevia biotech

Christof Paparella

Co-Founder

Ablevia biotech Email Formats

Ablevia biotech uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@ablevia.com), used 71.4% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@ablevia.com	71.4%
{first initial}.{last name}	j.doe@ablevia.com	28.6%

About Ablevia biotech

We develop injectable decoy biotherapeutics for the selective and quick removal of harmful circulating antibodies from blood. Our peptide-based decoys can be specifically adapted for vector-neutralizing antibodies in gene therapy, or drug-neutralizing anti-drug antibodies in enzyme- and factor replacement therapies (e.g. glycogen storage diseases, hemophilia & other rare conditions).

Ablevia biotech revenue & valuation

Annual revenue	$684,440
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$2,200,000
Total funding	No funding